Statin Side Effects:
What the Evidence Really Shows

For many people, the answer is yes — and the SAMSON trial suggests that quite specifically. Every participant in SAMSON had already stopped statins because of side effects, some of them having tried four or more different statins. Yet when given blinded tablets, the symptom burden on statin was no higher than on placebo.

Six months after the trial, 30 out of 60 participants (50%) had voluntarily restarted statin therapy — because the objective data from the trial had shown them that their symptoms had not been caused by the drug. This is a powerful finding: it suggests that for a significant proportion of people who believe they are statin-intolerant, a supervised rechallenge with good information may allow them to resume therapy.

If you stopped due to muscle aches, it is worth discussing a rechallenge with Dr Nijjer. Options include restarting the same statin, trying a different statin (different statins have different pharmacological profiles), trying a lower dose, or using alternate-day dosing. Rosuvastatin, for example, has a longer half-life that makes it suitable for alternate-day use in those sensitive to daily dosing.

No — the best available evidence shows they do not. This is one of the most frequently raised concerns, and it is specifically addressed by the CTT Collaboration's 2026 meta-analysis. Analysing data from 123,940 patients in 19 double-blind trials, the researchers found no significant excess risk for cognitive impairment, memory loss, or dementia (including Alzheimer's disease) in people taking statins compared to placebo.

This finding reinforces earlier dedicated studies, including the PROSPER and HPS trials, which specifically assessed cognition in statin users and found no adverse effect. The belief that statins impair memory appears to be driven by unblinded observational reports — patients who noticed memory symptoms while on a statin, attributed them to the drug, and reported them. Without a blinded comparison, it is impossible to know whether those symptoms would have occurred anyway, which the CTT analysis confirms they would have.

In fact, by reducing the risk of stroke and vascular dementia, statins may be protective of brain function in the long term — particularly in people at elevated cardiovascular risk.

The blinded trial evidence says no. The CTT Collaboration tested specifically for depression and psychiatric conditions across 123,940 patients in double-blind trials and found no statistically significant excess risk of depression compared with placebo.

This matters because depression is itself associated with cardiovascular disease — people with heart disease have higher rates of depression regardless of whether they are taking statins. Observational studies that have suggested a link between statins and depression are likely capturing this pre-existing association, rather than a causal drug effect. In blinded trials, where this confounding is controlled for, the association disappears.

If you are experiencing low mood or depression, this is important to discuss with your GP or cardiologist regardless of your statin status. Do not assume it is statin-caused and stop the medication without discussion.

Statins can cause a small rise in liver enzyme blood tests (transaminases) — this is a genuine and confirmed finding from the CTT data. The absolute annual excess is about 0.09% per year (roughly one extra case per 1,100 people per year), and it appears more pronounced with high-intensity statins such as atorvastatin 80 mg.

However, it is critical to understand what this means clinically. The CTT analysis found no significant excess for any serious liver outcome — specifically no excess for hepatitis, jaundice, liver failure, hepatic damage, or cholestasis. A rise in liver enzyme levels is a biochemical finding, not a diagnosis of liver disease. For the vast majority of people, it is clinically insignificant.

Routine liver function monitoring before starting statins used to be standard practice but is no longer universally recommended, because the risk of serious liver injury from statins is so low. If you develop symptoms that might suggest liver problems — jaundice (yellowing of the skin or eyes), severe abdominal pain, dark urine — you should seek medical attention promptly. But a slightly raised ALT on a routine blood test in a statin user without symptoms does not typically require the statin to be stopped.

No — the blinded trial data do not support this. The CTT Collaboration specifically tested for sleep-related disorders across the 123,940-patient dataset and found no significant excess risk compared with placebo. Sleep disturbance is listed in statin product information leaflets, but this appears to be based on unblinded case reports rather than blinded trial evidence.

It is worth noting that poor sleep is a very common problem in the general population, and particularly in people with cardiovascular disease, who often have other conditions such as sleep apnoea, anxiety, or discomfort from their heart condition. If you experience disrupted sleep while on a statin, the most likely explanation is one of these background factors rather than the medication.

If you take a fat-soluble statin (such as atorvastatin or simvastatin) and believe it affects your sleep, it is reasonable to discuss switching to a water-soluble statin (such as rosuvastatin or pravastatin) with your doctor, as these have a different brain penetration profile — though the clinical evidence for this making a difference is not strong.

No — and understanding where that leaflet comes from helps explain why. Statin product labels (the Summary of Product Characteristics, or SmPC) list adverse effects based largely on non-blinded observational data and case reports. If a patient reported a symptom while taking a statin — even a symptom they would almost certainly have experienced anyway — it may be logged and eventually added to the product label.

The CTT Collaboration systematically compiled every term listed in these leaflets for five statins — producing 66 conditions across 15 body systems — and then tested each one in a dataset of 123,940 patients from blinded trials. 62 out of 66 showed no significant excess over placebo. The authors explicitly concluded that "undesirable effect sections of statin product labels might overstate side effects and mislead clinicians and patients."

This means that reading a statin information leaflet and feeling alarmed by the length of the side effects list is itself a risk — because that alarm is exactly the mechanism by which the nocebo effect operates. Being informed that a drug may cause muscle pain, before taking it, increases the likelihood that you will feel muscle pain. The SAMSON trial demonstrated this directly.

The blinded trial evidence does not support this. The CTT Collaboration found no significant excess risk for peripheral or polyneuropathy (nerve damage causing tingling, numbness, or altered sensation) in statin users compared to placebo. Despite peripheral neuropathy appearing in some statin product labels, the randomised controlled trial evidence does not confirm a causal relationship.

Tingling in the hands and feet is a very common symptom with many causes, including vitamin B12 deficiency, diabetes (which is common in people who take statins), carpal tunnel syndrome, and cervical spine problems. In people at the age when statins are typically prescribed, background rates of peripheral neuropathy from other causes are quite high. This makes it easy to attribute a pre-existing or unrelated symptom to the most recently started medication.

If you have persistent tingling or numbness, please discuss this with your GP to rule out the above causes before attributing it to your statin.

Yes, statins do produce a confirmed, modest increase in the diagnosis of new type 2 diabetes — this is one of the few genuine confirmed effects and is not in dispute. The risk is dose-dependent (higher with high-intensity statins) and is concentrated almost entirely in people who already have pre-diabetes or metabolic syndrome — people who are very close to the diabetes threshold and would likely have developed it anyway in the near future.

However, this must be weighed against the cardiovascular benefit. For patients with established heart disease or significant cardiovascular risk, statins prevent approximately 1,000 serious cardiovascular events per 10,000 patients treated over five years — including heart attacks, strokes, and cardiac deaths. The excess diabetes risk is approximately 1 new diagnosis per 1,000 patients per year. Even in people at moderate cardiovascular risk, the reduction in heart attacks and strokes substantially outweighs the diabetes risk in the overwhelming majority of cases.

Moreover, diabetes itself is a risk factor for heart disease — and statins reduce the risk of cardiovascular events in people with diabetes at least as effectively as in those without it. The implication is that developing diabetes while on a statin does not negate the cardiovascular benefit of the statin.

If you are concerned about diabetes risk, the most important steps are maintaining a healthy weight, exercising regularly, and limiting refined carbohydrates — measures that benefit both diabetic and cardiovascular risk simultaneously.

The SAMSON trial provides an important insight here: it is very difficult to tell from timing alone. Participants in the trial who were experiencing symptoms were unable to distinguish statin months from placebo months based on symptom onset, symptom severity, or symptom relief on stopping. The pattern was identical — which is precisely why the trial was so powerful.

The clinical approach recommended by the SAMSON researchers — and used in cardiology practice — is a supervised rechallenge: stopping the statin, confirming symptoms resolve, and then restarting it (ideally without the patient knowing exactly when) to see whether symptoms recur. If symptoms recur only on the statin and not on placebo, that constitutes evidence of drug causation. If they occur equally in both conditions, that points to nocebo or background symptoms.

A few practical pointers: symptoms that are truly drug-caused tend to appear consistently across multiple statin rechallenges, tend to be associated with blood test abnormalities (raised creatine kinase for muscle damage), and tend to resolve within a few weeks of stopping. Symptoms that fluctuate independently of statin status, are not associated with blood test changes, and do not reliably resolve on stopping are more likely to be nocebo or coincidental.

If you have a symptom concern, please discuss it with Dr Nijjer before making changes to your medication.